IP Library Granted Patent US 9,839,671
Granted Patent B2
US 9,839,671 · App. 15/354,333 · Granted Dec 12, 2017

Peptide and uses therefor

Inventors: George Edward Rainger (Worcestershire, GB); Parth Narendran (Birmingham, GB); Helen McGettrick (Birmingham, GB); Myriam Chimen (Birmingham, GB)
Assignee: The University of Birmingham
A61K38/1709A61K48/0058C12N7/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,839,671
App. No.
15/354,333
Granted
Dec 12, 2017
Kind
B2
Abstract

Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N′-SVTEQGAELSNEER-C′ (SEQ ID NO: 1) or an analog thereof that inhibits T cell migration. Also provided is the peptide or its analog for use in the methods of treatment and/or prophylaxis of said condition. Also provided is a method for the treatment of Sjogren's syndrome by administration of a peptide comprising N′-SVTEQGAELSNEER-C′ to a patient in need thereof.

Claims (8)

1. A method for treatment of Sjogren's syndrome by administration, to a patient, of:

a peptide consisting of no more than 20 amino acids and comprising N′-SVTEQGAELSNEER-C′ (SEQ ID NO: 1) or an analogue or variant thereof that inhibits T cell migration; or

a chimeric or fusion protein comprising said peptide.

2. The method according to claim 1 , wherein the T cells are auto-reactive T cells.

3. The method according to claim 2 , wherein the peptide serves to inhibit the recruitment of auto-reactive T cells to the salivary glands.

4. The method according to claim 1 , wherein the peptide, analogue, variant, or chimeric or fusion protein thereof is administered in the form of a pharmaceutically acceptable composition.

5. The method according to claim 2 , wherein the peptide, analogue, variant, or chimeric or fusion protein thereof is administered in the form of a pharmaceutically acceptable composition.

6. The method according to claim 3 , wherein the peptide, analogue, variant, or chimeric or fusion protein thereof is administered in the form of a pharmaceutically acceptable composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2017
From: RAINGER, GEORGE EDWARD; NARENDRAN, PARTH; MCGETTRICK, HELEN; CHIMEN, MYRIAN
To: THE UNIVERSITY OF BIRMINGHAM
Reel/Frame 041276/0211 →
Priority Claims (1)
GB 1200555.9 · Jan 13, 2012 · national
Continuity (2)
Continuation In Part 14370881
Related Publication 20170151309A1 · Jun 1, 2017